China: Asia Pacific Competition Highlights, Q4 2021

In brief

China has set up a new National Anti-monopoly Bureau and published an updated draft amendment to the Anti-Monopoly Law. The API guidelines feature a "to-don't" list for the API sector, and the overseas compliance guidelines are tailored for antitrust compliance programs of Chinese businesses overseas. This past quarter has witnessed 45 failure-to-notify cases and 2 conditional approval cases.

This update was published as part of our quarterly newsletter, Asia Pacific Competition Highlights. Click here to access the full report, which covers the most notable antitrust developments across 10 Asia Pacific jurisdictions.


Institutional and legislative reforms signal stronger antitrust enforcement

China has set up a new National Anti-monopoly Bureau and published an updated draft amendment to the Anti-Monopoly Law.

On 18 November 2021, China's National Anti-monopoly Bureau (AMB) was established as the central-level antitrust regulator. The AMB consists of three departments in charge of competition policy cooperation, antitrust enforcement against anti-competitive behaviors and merger review respectively. There are 3 to 5 divisions under each department responsible for different work-streams.

Compared with its predecessor, the anti-monopoly bureau of the State Administration for Market Regulation, the AMB has been elevated to a vice-ministerial level central government authority. It is likely that this will allow for an increase in staffing and resources. During the AMB inauguration, the leadership emphasized that antitrust enforcement in the areas of platform economy, technology innovation, data security, and daily necessities for consumers would be a key priority.

On 23 October 2021, China published the latest proposed amendments to the Anti-Monopoly Law for public comments, which set out:

  • tougher penalties, including administrative fines for individuals, potential criminal liability, and significantly higher fines for procedural violations;
  • introduction of a 'stop-the-clock' mechanism for merger reviews;
  • possibility of safe harbors for certain types of non-hardcore anti-competitive conduct;
  • possible exemptions/defenses to the SAMR's previous hardline stance against resale price maintenance;
  • codifying certain categories of illegal conduct for online platforms and building on China's prior work in this area; and
  • a new public interest litigation mechanism initiated by People's Procuratorates.

China's ongoing institutional and legislative reforms in antitrust law signifies intensifying antitrust enforcement and indicates that antitrust compliance continues to be one of the top priorities for business operation in China.

For more information on the proposed amendments to the PRC Anti-monopoly Law, please see our client alert.

China releases two additional antitrust guidelines

The API guidelines feature a "to-don't" list for the API sector, and the overseas compliance guidelines are tailored for antitrust compliance programs of Chinese businesses overseas.

On the same day as the institutional reform (18 November 2021), China published two new antitrust guidelines, namely the Antimonopoly Guidelines in the Field of Active Pharmaceutical Ingredients ("API Guidelines") and the Guidelines for Overseas Antitrust Compliance of Undertakings ("Overseas Compliance Guidelines").

API, as an important raw material for pharmaceutical products, has become one of the top priorities of China's enforcement agenda in recent years. The API Guidelines address a number of common issues relating to the API sector based on the authority's past enforcement experience, including cartels in disguise as joint production, procurement, commercialization or bidding arranges; exchange of competitively sensitive information; hub-and-spoke types of anti-competitive arrangements; as well as collective abuse of dominance. The Guidelines act a helpful and practical reference guide for pharmaceutical companies' antitrust compliance in China.

Compared with the Anti-Monopoly Compliance Guidelines for Business Operators released in 2020, the Overseas Compliance Guidelines are designed for Chinese companies going abroad instead of business operators' activities in China. The aim of the Guidelines is to increase Chinese companies' awareness of overseas antitrust laws and to help establish a robust antitrust compliance program for their overseas businesses.

See our previous client alerts on antitrust compliance guidelines.

Merger control enforcement remains active in China

This past quarter has witnessed 45 failure-to-notify cases and two conditional approval cases.

Enforcement focus has not only stayed on the digital economy, but has also expanded to other sectors, such as auto parts and property management. However, the number of cases remains limited and the fines in these cases were RMB 300,000 (approx. USD 47,131), less than the fines in cases involving online platform operators, where the highest fine of RMB 500,000 (approx. USD 78,551) for failure to notify was imposed. As such, while the digital economy continues to dominate the antitrust agenda, there has been an upward trend of antitrust enforcement in other sectors. China has been intensifying the crackdown on procedural violations since late 2020, in particular those involving online platform operators with VIE structures.

The China antitrust regulator has also shown a continuous willingness and preference to impose behavioral remedies to sustain a degree of market competition and supply chain stability. Notably, there were two cases (both horizontal merger cases) which obtained conditional approvals in China. In one horizontal merger case in the machinery sector, the AMB imposed a series of behavioral remedies in order to maintain reliable and steady supply chain to Chinese customers. Whereas in the other horizontal merger case in the semiconductor sector, instead of imposing structural remedies (e.g., business/assets divestment), the merged entity was required to help a third party competitor's entry into the relevant market and to continue to expand capacity.

 

LOGO BM-FenXun bold-RGB (003)

© 2022 Baker & McKenzie FenXun (FTZ) Joint Operation Office. All rights reserved. Baker & McKenzie FenXun (FTZ) Joint Operation Office is a joint operation between Baker & McKenzie LLP, and FenXun Partners, approved by the Shanghai Justice Bureau. In accordance with the common terminology used in professional service organisations, reference to a "partner" means a person who is a partner, or equivalent, in such a law firm. This may qualify as “Attorney Advertising” requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.

Related alerts

 

Australia: Asia Pacific Competition Highlights, Q4 2021

Hong Kong: Asia Pacific Competition Highlights, Q4 2021

Indonesia: Asia Pacific Competition Highlights, Q4 2021

Japan: Asia Pacific Competition Highlights, Q4 2021

Malaysia: Asia Pacific Competition Highlights, Q4 2021

Singapore: Asia Pacific Competition Highlights, Q4 2021

Taiwan: Asia Pacific Competition Highlights, Q4 2021

Thailand: Asia Pacific Competition Highlights, Q4 2021

Vietnam: Asia Pacific Competition Highlights, Q4 2021

 

Contact Information
Zhi Bao
Partner at BakerMcKenzie
Beijing
Read my Bio
zhi.bao@bakermckenziefenxun.com

Copyright © 2024 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.